| Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy. | |
| | |
MedLine Citation:
|
PMID: 22323895 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
BACKGROUND: The purpose of this research was to compare the effects of niacin extended-release in combination with simvastatin (NER/S) versus atorvastatin monotherapy on high-density lipoprotein (HDL) particle number and size in patients with hyperlipidemia or dyslipidemia from the SUPREME study. METHODS: This was a post hoc analysis of patients (n = 137) who completed the SUPREME study and who had lipid particle number and size measurements at both baseline and at week 12 by nuclear magnetic resonance spectroscopy. Following ≥4 weeks without lipid-modifying therapy (washout period), the patients received NER/S 1000/40 mg/day for 4 weeks followed by NER/S 2000/40 mg/day for 8 weeks, or atorvastatin 40 mg/day for 12 weeks. Median percent changes in HDL particle number and size from baseline to week 12 were compared between the NER/S and atorvastatin treatment groups using the Wilcoxon rank-sum test. Distribution of HDL particle subclasses at week 12 was compared between the treatment groups using the Cochran-Mantel-Haenszel test. RESULTS: Treatment with NER/S resulted in a significantly greater percent reduction in small HDL particle number at week 12 compared with atorvastatin monotherapy (-1.8% versus 4.2%, P = 0.014), and a numerically greater percent increase in large HDL particle number (102.4% versus 39.2%, P = 0.078) compared with atorvastatin monotherapy. A significantly greater percent increase in HDL particle size from baseline at week 12 was observed with NER/S compared with atorvastatin (6.0% versus 1.3%, P < 0.001). NER/S treatment also resulted in a significant shift in HDL particle size from small and medium at baseline to large at week 12 (P < 0.0001). CONCLUSION: Treatment with NER/S resulted in larger favorable changes in number and size of HDL particle subclasses compared with atorvastatin monotherapy, including a numerically greater increase in number of large HDL particles, and a significantly greater decrease in number of small HDL particles compared with atorvastatin monotherapy. In addition, NER/S treatment resulted in a significant change in HDL particle size distribution from small and medium to large. |
| | |
Authors:
|
Peter P Toth; Kamlesh M Thakker; Ping Jiang; Robert J Padley |
Related Documents
:
|
19336375 - Governing peripherally inserted central venous catheters by combining continuous perfor... 18206455 - Central venous catheter placement at the time of extracorporeal membrane oxygenation de... 1358215 - Fibrin sleeve formation after long term brachial catheterisation with an implantable po... 12356145 - Should aspirin therapy be withheld before insertion and/or removal of a permanent perit... 15474275 - Frequency volume charts in the assessment and evaluation of treatment: how should we us... 18426345 - Effect of body mass index and ertapenem versus cefotetan prophylaxis on surgical site i... |
Publication Detail:
|
Type: Journal Article Date: 2012-01-25 |
Journal Detail:
|
Title: Vascular health and risk management Volume: 8 ISSN: 1178-2048 ISO Abbreviation: Vasc Health Risk Manag Publication Date: 2012 |
Date Detail:
|
Created Date: 2012-02-10 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101273479 Medline TA: Vasc Health Risk Manag Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 39-44 Citation Subset: IM |
Affiliation:
|
University of Illinois College of Medicine, Peoria, and CGH Medical Center, Sterling. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Allylic Amines as Key Building Blocks in the Synthesis of (E)-Alkene Peptide Isosteres.
Next Document: New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the...